As cancer care and research increasingly move towards targeted therapies and personalized care, VEGF-TKIs in combination with immune checkpoint inhibitors are an important class of therapeutics to focus on in SCCHN and other diseases. Here, VEGFA is linked to head and neck squamous cell carcinoma.